These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 31112713)

  • 1. Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future.
    Cannella N; Ubaldi M; Masi A; Bramucci M; Roberto M; Bifone A; Ciccocioppo R
    Neurosci Biobehav Rev; 2019 Aug; 103():384-398. PubMed ID: 31112713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical evidence that corticotropin-releasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism.
    Lowery EG; Thiele TE
    CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):77-86. PubMed ID: 20201818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?
    Pomrenze MB; Fetterly TL; Winder DG; Messing RO
    Alcohol Clin Exp Res; 2017 Dec; 41(12):1986-1999. PubMed ID: 28940382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapies for alcoholism: the old and the new.
    Olive MF
    CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):2-4. PubMed ID: 20232494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing Pharmacotherapy Development from Preclinical Animal Studies.
    Egli M
    Handb Exp Pharmacol; 2018; 248():537-578. PubMed ID: 29374834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Turning the clock ahead: potential preclinical and clinical neuropharmacological targets for alcohol dependence.
    Leggio L; Cardone S; Ferrulli A; Kenna GA; Diana M; Swift RM; Addolorato G
    Curr Pharm Des; 2010; 16(19):2159-18. PubMed ID: 20482506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A translational approach to novel medication development for protracted abstinence.
    Mason BJ; Higley AE
    Curr Top Behav Neurosci; 2013; 13():647-70. PubMed ID: 22351425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study.
    Kwako LE; Spagnolo PA; Schwandt ML; Thorsell A; George DT; Momenan R; Rio DE; Huestis M; Anizan S; Concheiro M; Sinha R; Heilig M
    Neuropsychopharmacology; 2015 Mar; 40(5):1053-63. PubMed ID: 25409596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism.
    Gehlert DR; Cippitelli A; Thorsell A; Lê AD; Hipskind PA; Hamdouchi C; Lu J; Hembre EJ; Cramer J; Song M; McKinzie D; Morin M; Ciccocioppo R; Heilig M
    J Neurosci; 2007 Mar; 27(10):2718-26. PubMed ID: 17344409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Heilig M; Egli M
    Pharmacol Ther; 2006 Sep; 111(3):855-76. PubMed ID: 16545872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurochemical Evidence of Preclinical and Clinical Reports on Target-Based Therapy in Alcohol Used Disorder.
    Prajapati SK; Bhaseen S; Krishnamurthy S; Sahu AN
    Neurochem Res; 2020 Feb; 45(2):491-507. PubMed ID: 31898084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutics for alcoholism: what's the future?
    Lawrence AJ
    Drug Alcohol Rev; 2007 Jan; 26(1):3-8. PubMed ID: 17364830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychopharmacology. Tackling alcoholism with drugs.
    Miller G
    Science; 2008 Apr; 320(5873):168-70. PubMed ID: 18403685
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats.
    Ji D; Gilpin NW; Richardson HN; Rivier CL; Koob GF
    Behav Pharmacol; 2008 Feb; 19(1):1-12. PubMed ID: 18195589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for relapse prevention of alcoholism: ten years of progress.
    Spanagel R; Kiefer F
    Trends Pharmacol Sci; 2008 Mar; 29(3):109-15. PubMed ID: 18262663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GABA
    Augier E; Dulman RS; Damadzic R; Pilling A; Hamilton JP; Heilig M
    Neuropsychopharmacology; 2017 Aug; 42(9):1789-1799. PubMed ID: 28294133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of molecular targets associated with ethanol toxicity and implications in drug development.
    Wang LL; Yang AK; He SM; Liang J; Zhou ZW; Li Y; Zhou SF
    Curr Pharm Des; 2010; 16(11):1313-55. PubMed ID: 20184550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems.
    Verplaetse TL; McKee SA; Petrakis IL
    Alcohol Res; 2018; 39(2):193-205. PubMed ID: 31198658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative Analysis of Genetic, Genomic, and Phenotypic Data for Ethanol Behaviors: A Network-Based Pipeline for Identifying Mechanisms and Potential Drug Targets.
    Bogenpohl JW; Mignogna KM; Smith ML; Miles MF
    Methods Mol Biol; 2017; 1488():531-549. PubMed ID: 27933543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.
    Litten RZ; Wilford BB; Falk DE; Ryan ML; Fertig JB
    Subst Abus; 2016; 37(2):286-98. PubMed ID: 26928397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.